Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: A randomised, double-blind, controlled phase I trial

The Lancet Respiratory Medicine

Volumn 3, Issue 12, 2015, Pages 953-962

  Spertini, François ^a   Audran, Régine ^a   Chakour, Reza ^a   Karoui, Olfa ^a   Steiner Monard, Viviane ^a   Thierry, Anne Christine ^a   Mayor, Carole E ^a   Rettby, Nils ^a   Jaton, Katia ^a   Vallotton, Laure ^a   Lazor Blanchet, Catherine ^a   Doce, Juana ^b   Puentes, Eugenia ^b   Marinova, Dessislava ^c   Aguilo, Nacho ^c   Martin, Carlos ^c,d,e  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Biofabri   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; LIVE VACCINE; MYCOBACTERIUM VACCINE; STERILE WATER;

ADULT; APPLICATION SITE DISCHARGE; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CELL COUNT; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INTERFERON GAMMA RELEASE ASSAY; MALE; MEMORY T LYMPHOCYTE; MUSCULOSKELETAL PAIN; NORMAL HUMAN; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TUBERCULOSIS; VACCINATION; WHOLE CELL; CLINICAL TRIAL; IMMUNIZATION;

ADULT; BCG VACCINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION; MALE; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED;

EID: 84948799448     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00435-X     Document Type: Article

References (30)

1. Global tuberculosis report 2014 2014, WHO, World Health Organization, Geneva.
2. Brites D, Gagneux S Co-evolution of Mycobacterium tuberculosis and Homo sapiens. Immunol Rev 2015, 264:6-24.
3. Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clinl Infect Dis 2014, 58:470-480.
4. Information sheet: observed rate of vaccine reactions Bacille-Calmette Guérin (BCG) vaccine April 2012, WHO, World Health Organization, Geneva.
5. Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 2002, 99:3684-3689.
6. Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007, 104:5596-5601.
7. Copin R, Coscollá M, Efstathiadis E, Gagneux S, Ernst JD Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG). Vaccine 2014, 32:5998-6004.
8. Marinova D, Gonzalo-Asensio J, Aguilo N, Martin C Recent developments in tuberculosis vaccines. Expert Rev Vaccines 2013, 12:1431-1448.
9. Arbues A, Aguilo JI, Gonzalo-Asensio J, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013, 31:4867-4873.
10. Walker KB, Brennan MJ, Ho MM, et al. The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine 2010, 28:2259-2270.
11. Pérez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001, 41:179-187.
12. Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, et al. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PloS One 2008, 3:e3496.
13. Solans L, Gonzalo-Asensio J, Sala C, et al. The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in Mycobacterium tuberculosis. PLoS Pathog 2014, 10:e1004183.
14. Gonzalo-Asensio J, Malaga W, Pawlik A, et al. Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator. Proc Natl Acad Sci USA 2014, 111:11491-11496.
15. Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 1999, 34:257-267.
16. Recommendations to assure the quality, safety and efficacy of BCG vaccines 2012, Expert Committee on Biological Standardization, World Health Organization, Geneva.
17. Harari A, Rozot V, Bellutti Enders F, et al. Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011, 17:372-376.
18. Soares AP, Scriba TJ, Joseph S, et al. Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008, 180:3569-3577.
19. Ellis RD, Hatherill M, Tait D, et al. Innovative clinical trial designs to rationalize TB vaccine development. tuberculosis (Edinb) 2015, 95:352-357.
20. Derrick SC, Yabe IM, Yang A, Morris SL Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011, 29:2902-2909.
21. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010, 182:1073-1079.
22. Lindenstrom T, Knudsen NP, Agger EM, Andersen P Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1-IL-2-secreting central memory cells. J Immunol 2013, 190:6311-6319.
23. Andersen P, Smedegaard B CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect Immun 2000, 68:621-629.
24. Lin PL, Dietrich J, Tan E, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012, 122:303-314.
25. Reiley WW, Shafiani S, Wittmer ST, et al. Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 2010, 107:19408-19413.
26. Seder RA, Darrah PA, Roederer M T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8:247-258.
27. Astarie-Dequeker C, Le Guyader L, Malaga W, et al. Phthiocerol dimycocerosates of M. tuberculosis participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids. PLoS Pathog 2009, 5:e1000289.
28. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
29. Thacher EG, Cavassini M, Audran R, et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS 2014, 28:1769-1781.
30. Grode L, Ganoza CA, Brohm C, Weiner J, Eisele B, Kaufmann SH Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013, 31:1340-1348.